% | $
Quotes you view appear here for quick access.

iShares Silver Trust Message Board

crecy_war_knight 3 posts  |  Last Activity: Jul 30, 2016 1:31 PM Member since: Jan 25, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • crecy_war_knight crecy_war_knight Jul 30, 2016 1:31 PM Flag

    I don't expect much at this point, not much sales. But it will be interesting if they mention how many Free samples they gave out.

    ACADIA Pharmaceuticals to Announce Second Quarter 2016 Financial Results on August 4, 2016

    ACADIA to Host Conference Call and Webcast on Thursday, August 4, 2016, at 5:00 p.m. Eastern Time

    SAN DIEGO--(BUSINESS WIRE)--Jul. 29, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2016 on Thursday, August 4, 2016, after the U.S. financial markets close. ACADIA's management will host a conference call and webcast on Thursday, August 4, 2016, at 5:00 p.m. Eastern Time to discuss ACADIA’s financial results and operations.

  • Reply to

    This board died

    by patalanico Jul 29, 2016 10:02 AM
    crecy_war_knight crecy_war_knight Jul 30, 2016 11:55 AM Flag

    Yahoo could have made a ton of money - they could have charged for the old message board. If reasonable I would have paid for it. They could have offered a few new features etc. I am surprised they didn't try it.

  • Reply to


    by linkuofm Jul 27, 2016 11:23 AM
    crecy_war_knight crecy_war_knight Jul 29, 2016 10:24 AM Flag

    OK here is AVXL's explanation of why the data looked bad.

    Anavex Confirms Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer’s Patients Presented at AAIC 2016

    New York, NY – July 29, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), confirms the information in the July 27, 2016 press release announcing positive results from the Phase 2a Alzheimer’s trial for ANAVEX 2-73.

    Dr. Norman Relkin, MD, PhD, an Alzheimer clinical trialist and an advisor to Anavex, commented: “To interpret the ANAVEX 2-73 results presented at the 2016 AAIC meeting, it is important to keep in mind the stated goals of this first in Alzheimer’s patients study. This was a Phase 2a study, primarily designed to determine which ANAVEX 2-73 dosages are safe to administer to mild to moderate stage Alzheimer’s patients. The study was successful in establishing the maximum tolerated dose and in revealing the range of ANAVEX 2-73 doses that are well-tolerated by Alzheimer patients. It also provided encouraging evidence that previously reported positive trends in certain cognitive and biologic measures persisted over a period of approximately 31 weeks. However, this analysis was based on pooled data from a relatively small number of subjects receiving a variety of doses. It is therefore unlikely that these findings reflect the full potential ANAVEX 2-73 in treating Alzheimer’s disease. It is unreasonable to draw conclusions about any limits to the long-term efficacy of ANAVEX 2-73 based on the interim Phase 2a findings, especially since no statistically significant decline from baseline was reported, which is impressive. Detailed pre-planned analysis of the pharmacodynamic results is in progress, which is one of the key factors of relevance for regulatory agencies and which will also determine the optimal dose for future studies."
    Anavex confirms that there has been no change with regards to its science, data or the fundamentals of the Company. Anavex remains

16.73-0.060(-0.36%)Oct 27 8:00 PMEDT